Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Contract drug manufacturer Lonza forecasts slower sales growth for 2026
    Finance

    Contract drug manufacturer Lonza forecasts slower sales growth for 2026

    Published by Global Banking & Finance Review®

    Posted on January 28, 2026

    2 min read

    Last updated: January 28, 2026

    Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:Sales growthMarket analysisInvestment opportunities

    Quick Summary

    Lonza predicts 11-12% sales growth for its CDMO business by 2026, with higher growth in the first half and profit margins above 32%.

    Table of Contents

    • Lonza's Sales Growth Forecast for 2026
    • Sales Growth Expectations
    • Core Profit Margin Insights
    • Dividend Proposal Details

    Lonza Anticipates Slower Sales Growth in 2026 for CDMO Business

    Lonza's Sales Growth Forecast for 2026

    Jan 28 (Reuters) - Lonza, the world's largest contract drug manufacturer, on Wednesday set 2026 targets for its contract development and manufacturing organization (CDMO) business, expecting slower sales growth of 11% to 12% at constant exchange rates and for its core profit margin to expand to above 32% of sales.

    Sales Growth Expectations

    The Swiss company added it expected sales growth to be higher in the first half of 2026 than in the second half.

    Core Profit Margin Insights

    In 2025, the CDMO business, which was split off from the capsule and health ingredients (CHI) business which Lonza is planning to sell, saw its sales grow 21.7% in constant currency to 6.5 billion Swiss francs ($8.5 billion).

    Dividend Proposal Details

    Analysts were expecting sales in the core business to grow 20.7% to 6.49 billion francs, a poll compiled by Vara showed.

    Lonza said sales growth was driven by a higher than expected contribution from its Vacaville site in California and good momentum across its mammalian, bioconjugates, small molecules, drug product and bioscience technology platforms.

    The Basel-based group said its core profit margin, or ratio of earnings before interest, taxes, depreciation and amortisation to sales in the continuing business, was 31.6% in 2025, above the 30.7% expected by analysts.

    The company also said it would propose a dividend of 5 francs per share, 25% higher than what was paid last year.

    ($1 = 0.7654 Swiss francs)

    (Reporting by Bernadette Hogg and Orest Dovhan in Gdansk, editing by Milla Nissi-Prussak)

    Key Takeaways

    • •Lonza forecasts 11-12% sales growth for its CDMO business by 2026.
    • •Core profit margins are expected to exceed 32% of sales.
    • •Sales growth is anticipated to be higher in the first half of 2026.
    • •Lonza is the world's largest contract drug manufacturer.
    • •The forecast is set at constant exchange rates.

    Frequently Asked Questions about Contract drug manufacturer Lonza forecasts slower sales growth for 2026

    1What is sales growth?

    Sales growth refers to the increase in revenue generated by a company over a specific period, typically expressed as a percentage. It indicates the company's ability to expand its business and attract more customers.

    2What is a profit margin?

    Profit margin is a financial metric that shows the percentage of revenue that exceeds the costs of goods sold (COGS). It reflects how efficiently a company is managing its expenses relative to its sales.

    3What is a financial projection?

    A financial projection is an estimate of future financial outcomes for a company based on historical data, market trends, and expected economic conditions. It helps businesses plan and allocate resources effectively.

    More from Finance

    Explore more articles in the Finance category

    Image for Rugby-Ford shines as England overwhelm dismal Wales 48-7 to kickstart Six Nations title bid
    Rugby-Ford shines as England overwhelm dismal Wales 48-7 to kickstart Six Nations title bid
    Image for Greenland foreign minister says US talks are positive but the outcome remains uncertain
    Greenland foreign minister says US talks are positive but the outcome remains uncertain
    Image for Hungary's opposition Tisza promises wealth tax, euro adoption in election programme
    Hungary's opposition Tisza promises wealth tax, euro adoption in election programme
    Image for Farmers report 'catastrophic damage to crops as Storm Marta hits Spain and Portugal
    Farmers report 'catastrophic damage to crops as Storm Marta hits Spain and Portugal
    Image for If US attacks, Iran says it will strike US bases in the region
    If US attacks, Iran says it will strike US bases in the region
    Image for Olympics-Biathlon-Winter Games bring tourism boost to biathlon hotbed of northern Italy
    Olympics-Biathlon-Winter Games bring tourism boost to biathlon hotbed of northern Italy
    Image for Analysis-Bitcoin loses Trump-era gains as crypto market volatility signals uncertainty
    Analysis-Bitcoin loses Trump-era gains as crypto market volatility signals uncertainty
    Image for NatWest closes in on $3.4 billion takeover of wealth manager Evelyn, Sky News reports
    NatWest closes in on $3.4 billion takeover of wealth manager Evelyn, Sky News reports
    Image for Stellantis-backed ACC drops plans for Italian, German gigafactories, union says
    Stellantis-backed ACC drops plans for Italian, German gigafactories, union says
    Image for US pushes Russia and Ukraine to end war by summer, Zelenskiy says
    US pushes Russia and Ukraine to end war by summer, Zelenskiy says
    Image for Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Image for Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    View All Finance Posts
    Previous Finance PostJERA considering how to utilise gas portfolio beyond Japan, says CEO
    Next Finance PostMorning Bid: Trump's talk downs the dollar